Universal Peace Federation: 70 Years After the Korean War, UPF Holds Online Summit for Peace and Reconciliation
The Rally of Hope, the third organized by UPF, is expected to draw much international participation this weekend. This rally, produced in Korea, will focus mainly on the Korean peninsula, seventy years after the outbreak of the Korean war (1950-53). UPF is an NGO in general consultative status with the Economic and Social Council of the United Nations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005660/en/
The Little Angels’ performance to thank the countries that came to South Korea’s aid in commemoration of the 70th anniversary of the outbreak of the Korean War (Photo: Business Wire)
Remembering yesterday’s war heroes; highlighting today’s peacemakers
In addition to featuring prominent global leaders, the renowned Little Angels Folk Ballet of Korea will perform a special tribute in honor of veterans of the Korean War.
Dr. Hak Ja Han Moon, the co-founder of UPF, will be keynote speaker. Her husband, the late Reverend Moon, was liberated by UN forces from the North Korean death camp of Heungnam. In her memoirs, Mother of Peace, Mrs. Moon explains how she escaped death several times during this conflict.
Further speakers include current and former heads of state and government whose countries were part of the United Nations forces in the Korean War: Sahle-Work Zewde, president of Ethiopia, the only current female head of State in Africa; Yves Leterme, Prime Minister of Belgium (2009-2011); Stephen Harper Prime Minister of Canada (2006-2015), now chairman of the International Democrat Union.
Other speakers include current heads of state whose countries have overcome domestic tensions and progressed toward national reconciliation: Salva Kiir, President of South Sudan, who recently invited the UPF chairman to attend the signing of the Juba peace agreement; Uhuru Kenyatta, President of Kenya and Mahinda Rajapaska, Prime Minister of Sri Lanka.
Mr. Jacques Marion, president of UPF Europe-Middle East, remarked that the Rally of Hope sets a strong signal for a peaceful unification. The interfaith prayer by religious leaders, the presence of Veterans of the Korean war representing the conflicting armies, will testify and sound an appeal for reconciliation on the divided peninsula, he said.
UPF states on its website that a main objective is the “peaceful reunification of the Korean peninsula and harmonious relations among the nations of Northeast Asia.” Directed towards this goal, UPF strives to realize the vision of a global democratic society, driven by the free-market and centered on family-based universal values.
This rally will be a dazzling display of digital technology from the land of K‑pop. A live internet audience of millions will be joined by an interactive audience using various social media apps.
Rally of Hope - Live Broadcast:
Date: November 22, 2020, 1:30 AM - 3:30 AM CET
Participants: VIPs & guests from all over the world (register at: rallyofhope.eu)
Highlights of the Rally (Online):
November 22, 2020, 6:00 PM - 7:00 PM CET
Participants: VIPs & guests from all over Europe & Middle East
Public registration for the rally (live or highlights) at: rallyofhope.eu
Media direct live streaming will use: peacelink.live
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005660/en/
Contact information
Peter Zoehrer, UPF Media Relations - Europe & Middle East
Phone: +43 (0) 6645238794
media@europe.upf.org
Websites: UPF.ORG & EUME.UPF.ORG
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin